|
|||||
|
|
| 结直肠癌辅助化疗进展 | |
| 引用本文： | 张冬梅. 结直肠癌辅助化疗进展[J]. 医学综述, 2008, 14(9): 1334-1336 |
| 作者姓名： | 张冬梅 |
| 作者单位： | 天津市第五中心医院肿瘤科,天津,300450 |
| 摘 要： | 结直肠癌辅助化疗经历了探索、争论近30年,先后确认5-FU/Lev和5-FU/CF为DukesC期结直肠术后标准的辅助化疗方案。随着新药奥沙利铂、伊立替康、卡培他宾、S-1等的上市,结肠癌的辅助化疗又登上了一个新台阶。口服卡培他宾可代替静脉注射5-FU/CF方案;FOLFOX优于5-FU/CF,有可能确立为DukesC期结肠癌术后标准的辅助化疗方案;靶向药物的诞生和免疫治疗有良好势头。 |
| 关 键 词： | 结直肠癌 辅助化疗 |
| 文章编号： | 1006-2084(2008)09-1334-03 |
| 修稿时间： | 2007-09-10 |
Advance of Colorectal Carcinoma Adjuvant Chemotherapy |
|
| ZHANG Dong-mei. Advance of Colorectal Carcinoma Adjuvant Chemotherapy[J]. Medical Recapitulate, 2008, 14(9): 1334-1336 | |
| Authors: | ZHANG Dong-mei |
| Affiliation: | ZHANG Dong-mei.(Center of Clinical Oncology,Tianjin Fifth Center Hospital,Tianjin,300450,China) |
| Abstract: | Chemotherapy for colorectal carcinoma had been argued about for nearly three decades.5-Fu/Lev and 5-Fu/CF were regarded as standard adjuvant chemotherapy regiment for Dukes'C colorectal cancer.Great progress has been made after many new anti-cancer agent,such as oxaliplatin,irinotecan,and capecitabine were found effective.Oral capecitabine matches that of venous administration of 5-FU/CF;FOLFOX is superior to and may take the place of 5-FU/CF in the standard adjuvant chemotherapy,and FOLFIRI seems to be bet... |
| Keywords: | Colorectal carcinoma Chemothrerapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |